Please login to the form below
Akorn Pharma
This page shows the latest Akorn Pharma news and features for those working in and with pharma, biotech and healthcare.
Fresenius says Akorn investigation could affect takeover
External ‘experts’ are investigating alleged breaches of data integrity requirements. Fresenius Kabi says its $4.3bn deal to acquire US generic drugmaker Akorn Pharma could be scuppered by an FDA probe ... period of 2016, with the declines all coming
Latest news
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital strategist
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
